TIS 0.00% 0.0¢ tissue therapies limited

defer us trials until cashflow

  1. 2,243 Posts.
    lightbulb Created with Sketch. 109
    Given how badly TIS has treated its band of loyal shareholders over the last 12 months, maybe they should consider deferring the US trials until we start generating cash and they should take immediate steps to eliminate all unnecessary expenditure until the CE mark issues...just a thought. Shareholders have copped massive losses over the last few months and no doubt they will cop even more over the weeks ahead. It would add insult to injury to come back to us and ask us to give them more money early next year. They should live within their means until this stuff-up is resoved.
 
watchlist Created with Sketch. Add TIS (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.